Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

Core Insights - Aptose Biosciences Inc. is developing a triple drug frontline therapy using tuspetinib (TUS) for newly diagnosed acute myeloid leukemia (AML) patients [1][4] - The TUSCANY study's abstract has been selected for poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting scheduled for December 6-9, 2025 [1][2] Presentation Details - The poster presentation will focus on the safety and efficacy of tuspetinib combined with standard care venetoclax and azacitidine for AML patients ineligible for induction chemotherapy [2] - The session will take place on December 6, 2025, from 5:30 PM to 7:30 PM at the OCCC - West Halls B3-B4 [2] Company Overview - Aptose is a clinical-stage biotechnology company focused on precision medicines for oncology, particularly in hematology [4] - Tuspetinib has shown activity as both a monotherapy and in combination therapy for relapsed or refractory AML and is being developed as a frontline triplet therapy for newly diagnosed AML [4]